This page uses javascripts, but your browser is not currently supporting JavaScripts. Please turn ON scripting in your web browser. Skip to Content

Buprenorphine
Home What is Buprenorphine? Buprenorphine Products DATA Physician Locator DATA 2000 FAQs Links En Español Physician Waiver Qualifications Waiver Notification Form Ongoing Web-based Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports To check on a physician's waivered status, please call the Buprenorphine Information Center at 1.866.287.2728. Nurses Guide to Buprenorphine Online Buprenorphine Course for Counselors

 
Buprenorphine Meeting May 10 through 11 2010

Disclosures Related to the Files Below

Buprenorphine in the Treatment of Opioid Addiction: Reassessment 2010
(sponsored by SAMHSA and NIDA)

Opening Remarks
The State of Buprenorphine Treatment (pdf, 0.8 MB) H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM
The NIDA Perspective-Research Wilson Compton, M.D., M.P.E. (No slides)
Buprenorphine Summit—Links to National Drug Strategy Goals (pdf, 0.5 MB) Keith Humphreys, Ph.D.
Epidemiology
Brief Introduction Jane Maxwell, Ph.D. (No slides)
National Physician Survey: Characteristics and Practices Chris-Ellyn Johanson, Ph.D. (Slides unavailable)
Indicators of Diversion and Abuse of Buprenorphine Products: Data from US Post-Marketing Surveillance Studies SODATA Charles R. Schuster, Ph.D. (Slides unavailable)
Buprenorphine Data from the RADARS® System (pdf, 1 MB) Nabarun Dasgupta, M.P.H.
Factors Affecting the Length of Stay in Opioid Dependence Treatment Using Buprenorphine and Methadone Hari Sagiraju, M.D., M.P.H. (Slides unavailable)
Epidemiology: The Federal Perspective
Outpatient Drug Utilization Trends for Buprenorphine Years 2002-2009 (pdf, 0.2 MB) Patty Greene, Pharm.D.
National Forensic Laboratory Information System (NFLIS) (pdf, 5 MB) Liqun Wong, M.S.
Drug-Related Emergency Department Visits Involving Buprenorphine (pdf, 0.1 MB) Elizabeth Crane, Ph.D., M.P.H.
PCSS Report
Physician Clinical Support System – Buprenorphine (PCSS-B) (pdf, 2 MB) David Fiellin, M.D.
DEA Keynote on Physician Inspection Initiative (pdf, 3.3 MB) Denise Curry, J.D.
Panel Discussion with representatives from DATA 2000 Training Organizations:
Models of Care Panel
Models of Care—Buprenorphine Experience in the Department of Veteran Affairs (pdf, 1.2 MB) Adam Gordon, M.D., M.P.H., FACP, FASAM
BHIVES: Buprenorphine Treatment in HIV Care David Fiellin, M.D. (Slides unavailable)
Opioid Treatment Program Jeffrey Craddock, M.D. (Slides unavailable)
MA State OBOT B: Nurse Care Manager Model (pdf, 0.4 MB) Colleen LaBelle, R.N., C.A.R.N.
Community Induction Sites (pdf, 0.3 MB) Herbert D. Kleber, M.D.
Models of Care—Indian Health Service (pdf, 0.2 MB) Anthony Dekker, D.O., FAOAAM
Buprenorphine's Efficacy: Lessons from Behavioral Economic Studies (pdf, 1.2 MB) Mark Greenwald, Ph.D.

Breakout Sessions/Action Planning Groups
Group 1: Data and Trend Monitoring
Jane Maxwell, Ph.D., and Shannon Mitchell, Ph.D. (No slides)

Group 2: Models of Care
Adam Gordon, M.D., M.P.H., FACP, FASAM, and Christopher Welsh, M.D. (Slides unavailable)

Group 3: Clinical Practice Improvement
George Kolodner, M.D., and Bertram Roberts, M.D., Dr.PH., MSHA, DTM&H, FACP (No slides)

Group 4: Addressing Further Research Needs in Buprenorphine Treatment
Petra Jacobs, M.D., M.P.H., and Herbert Kleber, M.D. (No slides)

Group 5: Report from Breakout Group: Educational Needs (pdf, 0.3 MB)
Joseph Liberto, M.D., and Judith Martin, M.D.

The Use of Buprenorphine in Treatment of Prescription Opioid Dependence Roger Weiss, M.D. (Slides unavailable)

Buprenorphine in the Treatment of Opioid Addiction: A Rural Appalachian Experience 2003-2010 (pdf, 9MB) Art Van Zee, M.D.

Suboxone Diversion: A Regional Perspective Edward W. Boyer, M.D., Ph.D. (Slides unavailable)

Economic Issues: Cost, Access, Coverage, and Outcomes

Buprenorphine Cost Effectiveness Bruce R. Schackman, Ph.D. (Slides unavailable)
Impact of Buprenorphine on Medical and Behavioral Health Utilization (pdf, 0.2 MB) Mark Friedlander, M.D.
Financing Buprenorphine in the Treatment of Opioid Addiction (pdf, 0.2 MB) Mady Chalk, Ph.D., M.S.W.

Minimizing the Risks of Diversion Panel

Best Practices in Buprenorphine Prescribing: Improving Treatment in Appalachia and Wisconsin through CME (pdf, 0.3 MB) Michelle Lofwall, M.D.
MAPS—Michigan Automated Prescription System Michael Wissel, R.Ph. Part 1 (pdf, 1.2 MB), Part 2 (pdf, 0.6 MB)
Risk Evaluation and Mitigation Strategies (REMS): An Overview Mary Willy, Ph.D. (Slides unavailable)
Suboxone and Subutex Risk Management Program Vicky Seeger R.Ph. (Slides unavailable)

Special Populations Panel

Continuing Buprenorphine/Naloxene with Counseling is More Effective than Detoxification with Counseling for 15–21 Year Old Opioid Addicts (pdf, 1.2 MB) George Woody, M.D.
Pregnant Women Results from the MOTHER Study Karol Kaltenbach, Ph.D. (Slides unavailable)
Buprenorphine Treatment for Prisoners Robert Schwartz, M.D. (Slides unavailable)
S/L Buprenorphine and Pain Management: New Tricks for an Old Molecule (pdf, 0.7 MB) Howard A. Heit, M.D., FACP, FASAM
New Formulations of Buprenorphine: What’s on the Horizon Eric C. Strain, M.D. (Slides unavailable)

 


Go to U.S. Department of Health and Human Services
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov

* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.

Go to Division of Pharmacologic Therapies